<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073736</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-101</org_study_id>
    <nct_id>NCT00073736</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase 1/2 Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MB07133 in Subjects With Unresectable Hepatocellular Carcinoma and Child-Pugh Class A Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ligand Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is&#xD;
      being developed for the treatment of inoperable HCC, using a platform technology known as&#xD;
      HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for&#xD;
      this study is to determine the safety and tolerability of MB07133.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the maximum tolerated dose of MB07133 when administered as a 7-day continuous&#xD;
      i.v. To characterize the safety profile and the pharmacokinetics of MB07133 and metabolites&#xD;
      during and after continuous infusion. To determine the effect of MB07133 on hepatocellular&#xD;
      carcinoma (HCC) tumor size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>7-day continuous infusion every 28-days as tolerated</time_frame>
    <description>To determine the dose-limiting toxicities (DLT) of MB07133; To determine the maximum-tolerated continuous infusion dose (MTD) of MB07133</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine effect of MB07133 on tumor size</measure>
    <time_frame>28 day cycles</time_frame>
    <description>To determine the effect on HCC tumor size by using CT scanning, alpha-fetoprotein (AFP) concentration, and performance status.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>MB07133 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day continuous infusion in 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB07133 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day continuous infusion in 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB07133 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day continuous infusion in 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB07133 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day continuous infusion in 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB07133 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day continuous infusion in 28-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB07133 300mg/m2/day</intervention_name>
    <description>7-day continuous infusion in 28-day cycles</description>
    <arm_group_label>MB07133 Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB07133 600 mg/m2/day</intervention_name>
    <description>7-day continuous infusion in 28-day cycles</description>
    <arm_group_label>MB07133 Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB07133 1200 mg/m2/day</intervention_name>
    <description>7-day continuous infusion in 28-day cycles</description>
    <arm_group_label>MB07133 Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB07133 1800 mg/m2/day</intervention_name>
    <description>7-day continuous infusion in 28-day cycles</description>
    <arm_group_label>MB07133 Dose Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MB07133 2400 mg/m2/day</intervention_name>
    <description>7-day continuous infusion in 28-day cycles</description>
    <arm_group_label>MB07133 Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of local unresectable HCC confirmed by histology using fine&#xD;
             needle aspirate (FNA) or liver biopsy. &quot;Local&quot; is defined as disease either restricted&#xD;
             to the liver or contiguous with the liver and no identifiable extrahepatic disease.&#xD;
&#xD;
          -  Patients with Child-Pugh Class A liver function. For purposes of this trial, an&#xD;
             eligible patient must not have Encephalopathy or Ascites and the total Child-Pugh&#xD;
             score cannot be greater than 6 at baseline&#xD;
&#xD;
          -  Males or females 18 years of age or older&#xD;
&#xD;
          -  Ability to provide written informed consent before initiation of any study-related&#xD;
             procedures and ability, in the opinion of the Principal Investigator, to comply with&#xD;
             all the requirements of the study&#xD;
&#xD;
          -  Male and female subjects who are surgically sterile, who remain abstinent, or who&#xD;
             agree to practice double barrier forms of birth control from screening through 30 days&#xD;
             (females) and 90 days (males), from the last dose of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or presence of clinically significant acute or unstable cardiovascular,&#xD;
             cerebrovascular (stroke), renal, GI, pulmonary, immunological (with the exception of&#xD;
             the presence of hepatitis B virus [HBV], HCV hepatitis, or cirrhosis), endocrine, or&#xD;
             central nervous system disorders&#xD;
&#xD;
          -  Patient has a history of cancer other than hepatocellular (excluding resected basal&#xD;
             cell carcinoma; or curatively resected stage 1 or less cervical cancer if disease free&#xD;
             for 5 years or more).&#xD;
&#xD;
          -  Patients with distant metastasis or extrahepatic disease&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status score of greater than&#xD;
             or equal to 2&#xD;
&#xD;
          -  Current encephalopathy or current treatment for encephalopathy&#xD;
&#xD;
          -  History of drug or alcohol abuse within 6 months before screening&#xD;
&#xD;
          -  History of, or current clinically significant mental disorder or an antagonistic&#xD;
             personality that compromises the validity of the informed consent&#xD;
&#xD;
          -  A documented variceal hemorrhage within 4 months of screening&#xD;
&#xD;
          -  Neutrophil count less than or equal to 1,500/mm3, platelet count less than or equal to&#xD;
             100,000/mm3, hemoglobin less than or equal to 8.5 g/dL, or a Prothrombin Time (INR)&#xD;
             greater than 1.3 (vitamin K supplementation allowed)&#xD;
&#xD;
          -  Serum creatinine greater than 1.1 times the upper limit of normal&#xD;
&#xD;
          -  History of human immunodeficiency virus or acquired immune deficiency syndrome&#xD;
&#xD;
          -  Use of an investigational drug or product or participation in a drug study within 30&#xD;
             days before dosing&#xD;
&#xD;
          -  Liver function defined as: serum bilirubin greater than 1.5 times the upper limit of&#xD;
             normal or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&#xD;
             greater than 5 times upper limit of normal, or serum albumin less than 3.2 g/dL&#xD;
&#xD;
          -  History of gout or abnormal uric acid metabolism&#xD;
&#xD;
          -  The clinical presence of ascites&#xD;
&#xD;
          -  Treatment of HCC within 30 days of screening by chemotherapy or treatment of the&#xD;
             target lesion(s) by chemoembolization, PEI, or surgery&#xD;
&#xD;
          -  Radiofrequency (&quot;RF&quot;) ablation of the target lesion(s) within 60 days of screening&#xD;
&#xD;
          -  Subjects with a life expectancy of less than 12 weeks&#xD;
&#xD;
          -  Subjects having received an organ transplant&#xD;
&#xD;
          -  Subjects currently receiving coumadin or heparin&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabela Niculae, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Metabasis Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital - Comprehensive Cancer Trial Unit</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Services General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Nei Hu District</state>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>December 3, 2003</study_first_submitted>
  <study_first_submitted_qc>December 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2003</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Project Management</name_title>
    <organization>Ligand Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Hepatocellular</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Liver</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

